Moderna diversifies vaccine portfolio with promising clinical trial results

Summary: Moderna announced positive clinical trial data for three experimental vaccines beyond its Covid jab, moving them to final stage studies. The company aims to diversify its product portfolio due to declining Covid vaccine demand. Moderna's vaccine business has a $52 billion market potential. It has five shots in late-stage trials, including a combination Covid-flu vaccine. Blackstone will fund up to $750 million for Moderna's flu shot program. CEO Bancel emphasizes focus on execution and patient impact.

Full article